Translational research in central nervous system drug discovery

Abstract

Of all the therapeutic areas, diseases of the CNS provide the biggest challenges to translational research in this era of increased productivity and novel targets. Risk reduction by translational research incorporates the “learn” phase of the “learn and confirm” paradigm proposed over a decade ago. Like traditional drug discovery in vitro and in laboratory animals, it precedes the traditional phase 1–3 studies of drug development. The focus is on ameliorating the current failure rate in phase 2 and the delays resulting from suboptimal choices in four key areas: initial test subjects, dosing, sensitive and early detection of therapeutic effect, and recognition of differences between animal models and human disease. Implementation of new technologies is the key to success in this emerging endeavor.

DOI: 10.1602/neurorx.2.4.671
050100150'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

613 Citations

Semantic Scholar estimates that this publication has 613 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hurko2005TranslationalRI, title={Translational research in central nervous system drug discovery}, author={Orest Hurko and John L. Ryan}, journal={NeuroRX}, year={2005}, volume={2}, pages={671-682} }